Skip to main content
SpringerLink
Log in

Bowman-Birk Inhibitor Concentrate Reduces Colon Inflammation in Mice with Dextran Sulfate Sodium-Induced Ulcerative Colitis

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Bowman-Birk inhibitor concentrate (BBIC) is asoybean extract enriched in the BowmanBirk inhibitor, aprotein protease inhibitor. The Bowman-Birk inhibitorcan inhibit proteases released from inflammation mediating cells and suppress superoxide anionradical secretion from immunocytes. This studyinvestigates the ability of Bowman-Birk inhibitorconcentrate to inhibit colon inflammation in the dextransulfate sodium model of ulcerative colitis, aninflammatory bowel disease. When compared to mice on astandard diet, mice given food supplemented with 0.5%BBIC during and after dextran sulfate sodium treatment showed suppression of three of four scoredhistopathological inflammation criteria (P < 0.01),total histopathological score (P < 0.01), a 15% lowermortality rate (P < 0.01), and a delayed onset of mortality. We conclude that dietaryBowman-Birk inhibitor concentrate can beneficiallyaffect dextran sulfate sodium-treated mice and may beuseful in the treatment of human inflammatory boweldiseases, particularly ulcerative colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR: Nanomolar concentrations of Bowman-Birk soybean protease inhibitors suppress X-ray induced transformation in vitro. Proc Natl Acad Sci USA 82:5395–5399, 1985

    Google Scholar 

  2. Kennedy AR: Anticarcinogenic activity of protease inhibitors: Overview. In Protease Inhibitors as Cancer Chemopreventive Agents. W Troll, AR Kennedy (eds). New York, Plenum Press, 1993, pp 9–64

    Google Scholar 

  3. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC: Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19:281–302, 1993

    Google Scholar 

  4. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF: Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biochemistry (Moscow) 58:1437–1444, 1993

    Google Scholar 

  5. Tikhonova TV, Gladysheva IP, Kazanshaya NF, Larionova NI: Hydrolysis of elastin by human leukocyte elastase and cathepsin G: Inhibition by Bowman Birk type inhibitor. Biochemistry (Moscow) 59:1295–1299, 1994

    Google Scholar 

  6. Gladysheva IP, Larionova NI, Gladysheva DP, Tikhonova TV, Kazanskaia NF: The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biochemistry (Moscow) 59(4):513–518, 1994

    Google Scholar 

  7. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344:133–138, 1997

    Google Scholar 

  8. Frenkel K, Chrazan K, Ryan CA, Wiesner R, Troll W: Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 8:1207–1212, 1987

    Google Scholar 

  9. Podolsky DK: Inflammatory bowel disease. N Engl J Med 325:928-937, 1008–1016, 1991

    Google Scholar 

  10. Glickman RM: Inflammatory Bowel disease: Ulcerative colitis and Crohn's disease. In Harrison's Principles of Internal Medicine. KJ Isselbacher, et al (eds). New York, McGraw-Hill, 1994, pp 1403-1417

    Google Scholar 

  11. Bohe M: Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. Scand J Gastroenterol 22:59–64, 1987

    Google Scholar 

  12. Bohe M, Genell S, Ohlsson K: Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease. Scand J Gastroenterol 21:598–604, 1986

    Google Scholar 

  13. Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek J, Kennedy AR, Lichtenstein GR, Billings PC: Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969–1980, 1996

    Google Scholar 

  14. Hanauer SB, Baert F: Medical therapy of inflammatory bowel disease. Med Clin North Am 78:1413–1426, 1994

    Google Scholar 

  15. Das KM: Some current perspectives on the etiology and pathogenesis of ulcerative colitis. In Ulcerative Colitis.CA O'Morain (ed). Boca Raton, Florida, CRC Press, 1991, pp 47–54

    Google Scholar 

  16. Wargovich MJ, Bauer AR, Hu PJ, Sumiyoshi H: Dietary factors and colorectal cancer. Gastroenterol Clin North Am 7:727–745, 1988

    Google Scholar 

  17. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L: Ulcerative colitis and adenocarcinoma of the colon in G-alpha-i2-deficient mice. Nature Genet 10:143–150, 1995

    Google Scholar 

  18. Dayal Y, DeLellis RA: The gastrointestinal tract. In Robbins Pathologic Basis of Disease. RS Cotran, V Kumar, SL Robbins (eds). Philadelphia, WB Saunders, 1989, pp 827–910

    Google Scholar 

  19. Pena AS, Shivanada S, Mayberry JF: Epidemiology of ulcerative colitis. In Ulcerative Colitis. CA O'Morain (ed). Boca Raton, Florida, CRC Press, 1991, pp 1–8

    Google Scholar 

  20. Senda S, Fujiyama Y, Bamba T, Hosoda S: Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 32:350–354, 1993

    Google Scholar 

  21. Birk Y: Proteinase inhibitors from plant sources. Methods Enzymol 45:695–751, 1975

    Google Scholar 

  22. Birk Y: The Bowman-Birk inhibitor. Int J Peptide Protein Res 25:113–131, 1985

    Google Scholar 

  23. Billings PC, Clair WHS, Maki PA, Kennedy AR: Distribution of the Bowman-Birk inhibitor in mice following oral administration. Cancer Lett 62:191–197, 1992

    Google Scholar 

  24. Yavelow J, Finlay TH, Kennedy AR, Troll W: Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 43:2454–2459, 1983

    Google Scholar 

  25. Billings PC, Brandon DL, Habres JM: Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 27:903–908, 1991

    Google Scholar 

  26. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium in experimental murine colitis. Lab Invest 69:238–249, 1993

    Google Scholar 

  27. Cooper HS, Murthy SNS: Displasia in dextran sulfate sodium (DSS) experimental murine colitis.Gastroenterology 106:A378, 1994

    Google Scholar 

  28. Dielman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO: Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643–1652, 1994

    Google Scholar 

  29. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagake Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702, 1990

    Google Scholar 

  30. Zar JH: Biostatistical Analysis. Upper Saddle River, New Jersey, Prentice Hall, 1996

    Google Scholar 

Download references

Authors
  1. Jeffrey H. Ware
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. Steven Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Newberne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ann R. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ware, J.H., Wan, X.S., Newberne, P. et al. Bowman-Birk Inhibitor Concentrate Reduces Colon Inflammation in Mice with Dextran Sulfate Sodium-Induced Ulcerative Colitis. Dig Dis Sci 44, 986–990 (1999). https://doi.org/10.1023/A:1026616832119

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026616832119

Search

Navigation